MA46042A - Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin - Google Patents
Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallinInfo
- Publication number
- MA46042A MA46042A MA046042A MA46042A MA46042A MA 46042 A MA46042 A MA 46042A MA 046042 A MA046042 A MA 046042A MA 46042 A MA46042 A MA 46042A MA 46042 A MA46042 A MA 46042A
- Authority
- MA
- Morocco
- Prior art keywords
- disubstituted
- steroid
- pyrazolyl
- crystalline
- Prior art date
Links
- VVUQRXPUVKXAIO-XFUVECHXSA-N 19-nor-5-androstenediol Chemical compound C1[C@@H](O)CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 VVUQRXPUVKXAIO-XFUVECHXSA-N 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46042A true MA46042A (fr) | 2019-07-03 |
Family
ID=59772778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046042A MA46042A (fr) | 2016-08-23 | 2017-08-23 | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11236121B2 (fr) |
| EP (2) | EP3504189A1 (fr) |
| JP (3) | JP2019524853A (fr) |
| KR (2) | KR20230079470A (fr) |
| CN (4) | CN115974956A (fr) |
| AR (3) | AR109393A1 (fr) |
| AU (3) | AU2017315682B2 (fr) |
| BR (1) | BR112019003637A2 (fr) |
| CA (1) | CA3034262A1 (fr) |
| CL (2) | CL2019000477A1 (fr) |
| CO (1) | CO2019002596A2 (fr) |
| EA (1) | EA201990565A1 (fr) |
| EC (1) | ECSP19020141A (fr) |
| IL (2) | IL302480A (fr) |
| JO (3) | JOP20190022B1 (fr) |
| MA (1) | MA46042A (fr) |
| MX (2) | MX393240B (fr) |
| MY (1) | MY200479A (fr) |
| PE (2) | PE20241580A1 (fr) |
| PH (1) | PH12019500375A1 (fr) |
| SG (1) | SG11201901445TA (fr) |
| TW (4) | TWI854445B (fr) |
| WO (1) | WO2018039378A1 (fr) |
| ZA (1) | ZA201901051B (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| WO2014169831A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci |
| CN113527400B (zh) | 2013-04-17 | 2024-06-28 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| RU2019126333A (ru) | 2013-04-17 | 2019-10-08 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| WO2015010054A2 (fr) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (fr) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, leurs compositions et utilisations |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| MX2021004492A (es) | 2014-10-16 | 2022-12-05 | Sage Therapeutics Inc | Composiciones para el tratamiento de trastornos del snc. |
| SMT202000414T1 (it) | 2014-10-16 | 2020-09-10 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| ME03749B (fr) | 2014-11-27 | 2021-04-20 | Sage Therapeutics Inc | Compositions et procédés pour traiter des troubles du snc |
| DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| WO2018013613A1 (fr) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| CA3030420C (fr) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | Steroides neuroactifs substitues en c7, c12 et c16 et methodes d'utilisation associees |
| CN115974956A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| CA3075038A1 (fr) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | Steroides neuroactifs et leurs methodes d'utilisation |
| EP3681510A1 (fr) * | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | Stéroïde c21-n-pyrazolyl c3,3-disubstitué 19 nor, et procédés d'utilisation de ce dernier |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| CN117959309A (zh) * | 2018-06-12 | 2024-05-03 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| IL312610B2 (en) | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
| CN111454318A (zh) | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| US12122804B2 (en) | 2019-01-31 | 2024-10-22 | Shenzhen Rentai Pharmatech Ltd. | γ-aminobutyric acid modulator crystal form X, preparation method and application thereof |
| US20220220149A1 (en) | 2019-05-28 | 2022-07-14 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| EP4011897A4 (fr) * | 2019-08-07 | 2024-02-21 | Shanghai Hansoh Biomedical Co., Ltd. | Sel et forme cristalline d'un régulateur de dérivé de stéroïde |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| BR112023000990A2 (pt) * | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| US20230372365A1 (en) * | 2020-10-01 | 2023-11-23 | Andrew D. Levin | Methods of treating fibromyalgia with neuroactive steroids |
| US20240122945A1 (en) | 2021-01-28 | 2024-04-18 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| US20240245711A1 (en) * | 2021-03-17 | 2024-07-25 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| TW202308654A (zh) * | 2021-04-29 | 2023-03-01 | 美商賽吉醫療公司 | 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 |
| CA3217866A1 (fr) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Steroide neuroactif destine a etre utilise dans le traitement d'un trouble depressif majeur et de la depression post-partum chez une femme allaitante |
| KR20240037975A (ko) | 2021-07-28 | 2024-03-22 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드의 결정질 형태 |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
| WO2026055127A2 (fr) | 2024-09-04 | 2026-03-12 | Sage Therapeutics, Inc., A Wholly Owned Subsidiary Of Supernus Pharmaceuticals, Inc. | Procédé de production d'un modulateur de récepteur gaba |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| SK9742002A3 (en) | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| DE60335788D1 (de) | 2002-02-08 | 2011-03-03 | Ono Pharmaceutical Co | Piperidinderivatverbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten |
| WO2011079047A1 (fr) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Procédés pour réduire l'occurrence d'accouchements prématurés et d'autres conditions associées à une grossesse |
| CA2843436A1 (fr) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Nouveaux steroides substitues en 17? par un heteroaryle, capables de moduler les recepteurs gabaa |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| SMT202000008T1 (it) | 2012-01-23 | 2020-03-13 | Sage Therapeutics Inc | Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014028398A2 (fr) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation de crises épileptiques par une polythérapie à l'aide de benzodiazépines et de neurostéroïdes |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| WO2014058736A1 (fr) | 2012-10-08 | 2014-04-17 | Washington University | Stéroïdes neuroactifs 19-alcoxy-17(20)-z-vinylcyano-substitués, promédicaments associés et méthodes de traitement les utilisant |
| ES2973320T3 (es) | 2012-11-30 | 2024-06-19 | Univ California | Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto |
| TR201808616T4 (tr) | 2012-12-18 | 2018-07-23 | Sage Therapeutics Inc | Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri. |
| CN113527400B (zh) | 2013-04-17 | 2024-06-28 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| RU2019126333A (ru) | 2013-04-17 | 2019-10-08 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci |
| WO2015010054A2 (fr) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN106661078A (zh) | 2014-05-29 | 2017-05-10 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| WO2015195962A1 (fr) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, leurs compositions et utilisations |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| SMT202000414T1 (it) | 2014-10-16 | 2020-09-10 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| MX2021004492A (es) | 2014-10-16 | 2022-12-05 | Sage Therapeutics Inc | Composiciones para el tratamiento de trastornos del snc. |
| ME03749B (fr) | 2014-11-27 | 2021-04-20 | Sage Therapeutics Inc | Compositions et procédés pour traiter des troubles du snc |
| DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| EP3280420B1 (fr) | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions et méthodes permettant de traiter des troubles du snc |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| US20180250313A1 (en) | 2015-09-08 | 2018-09-06 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| AU2016338672A1 (en) | 2015-10-16 | 2018-04-12 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| WO2017087864A1 (fr) | 2015-11-20 | 2017-05-26 | Sage Therapeutics, Inc. | Composés et leurs méthodes d'utilisation |
| RU2766155C2 (ru) | 2016-03-08 | 2022-02-08 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применения |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| CA3030420C (fr) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | Steroides neuroactifs substitues en c7, c12 et c16 et methodes d'utilisation associees |
| WO2018013613A1 (fr) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| CN115974956A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (fr) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | Méthodes de traitement de l'épilepsie et d'affections associées à kcnti |
| CA3073925A1 (fr) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | Traitement d'affections du snc |
| CA3075038A1 (fr) | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | Steroides neuroactifs et leurs methodes d'utilisation |
| WO2019051477A1 (fr) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | Méthodes de traitement de l'épilepsie ou de l'état de mal épileptique |
| EP3681510A1 (fr) | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | Stéroïde c21-n-pyrazolyl c3,3-disubstitué 19 nor, et procédés d'utilisation de ce dernier |
| US20190160078A1 (en) | 2017-11-10 | 2019-05-30 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disorders |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| US20220315621A1 (en) | 2017-12-22 | 2022-10-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| IL275562B2 (en) | 2017-12-22 | 2024-07-01 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| MA51568A (fr) | 2018-01-12 | 2021-04-21 | Sage Therapeutics Inc | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central |
| CN117959309A (zh) | 2018-06-12 | 2024-05-03 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| DK3864022T3 (da) | 2018-10-12 | 2023-12-18 | Sage Therapeutics Inc | Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser |
| JP7534291B2 (ja) | 2018-10-19 | 2024-08-14 | セージ セラピューティクス， インコーポレイテッド | ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 |
| IL312610B2 (en) | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
| WO2020132504A1 (fr) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs de 3.alpha.-hydroxy-17.bêta.-amide et compositions associées |
| TWI855081B (zh) | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| WO2020264495A1 (fr) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions et méthodes de traitement de troubles du système nerveux central |
| EP3990468A1 (fr) | 2019-06-27 | 2022-05-04 | Sage Therapeutics, Inc. | Composés pour le traitement de troubles du système nerveux central |
| TWI896547B (zh) | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| AU2020395246A1 (en) | 2019-12-05 | 2022-06-16 | Sage Therapeutics, Inc. | A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
| IL296371A (en) | 2020-03-18 | 2022-11-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| EP4172171A1 (fr) | 2020-06-24 | 2023-05-03 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl-substitués et compositions associées |
| BR112023000990A2 (pt) | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| MX2023006063A (es) | 2020-11-25 | 2023-08-09 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central. |
| US20240122945A1 (en) | 2021-01-28 | 2024-04-18 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| US20240148756A1 (en) | 2021-02-18 | 2024-05-09 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| US20240245711A1 (en) | 2021-03-17 | 2024-07-25 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| MX2023012013A (es) | 2021-04-12 | 2024-05-31 | Sage Therapeutics Inc | Tratamiento del temblor esencial. |
| CA3217866A1 (fr) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Steroide neuroactif destine a etre utilise dans le traitement d'un trouble depressif majeur et de la depression post-partum chez une femme allaitante |
| TW202308654A (zh) | 2021-04-29 | 2023-03-01 | 美商賽吉醫療公司 | 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
-
2017
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 CA CA3034262A patent/CA3034262A1/fr active Pending
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 MX MX2019002193A patent/MX393240B/es unknown
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko active Pending
- 2017-08-23 MY MYPI2019000844A patent/MY200479A/en unknown
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es not_active Application Discontinuation
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 TW TW112101437A patent/TWI854445B/zh active
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/fr not_active Withdrawn
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 TW TW113108231A patent/TWI904593B/zh active
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 TW TW114114606A patent/TW202604538A/zh unknown
- 2017-08-23 IL IL315950A patent/IL315950B1/en unknown
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 PE PE2024000634A patent/PE20241580A1/es unknown
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt not_active Application Discontinuation
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/fr not_active Ceased
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Ceased
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/fr active Pending
-
2018
- 2018-03-01 JO JOJO/P/2022/0305A patent/JOP20220305A1/ar unknown
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
- 2022-11-10 JO JOJO/P/2022/0304A patent/JOP20220304A1/ar unknown
-
2023
- 2023-08-24 US US18/455,324 patent/US12358942B2/en active Active
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732B2/en active Active
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja not_active Withdrawn
-
2025
- 2025-06-11 US US19/234,808 patent/US20250304615A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278487B (en) | 19- nor c3, 3- dimethomer c21- n- pyrazole Steroids and methods of using them | |
| IL258844A (en) | Methods for culturing cells and kits and apparatus for same | |
| NO2022020I1 (no) | drospirenon /estetrol | |
| IL315950B1 (en) | 19-NOR C3,3-dimethomer C21-N-pyrazolyl steroid crystalline | |
| IL254734B1 (en) | Modified t cells and methods of making and using the same | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| PL3653221T3 (pl) | Przeciwciała anty-pvrig i sposoby ich zastosowania | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| EP3394250A4 (fr) | Reprogrammation cellulaire | |
| DK3149018T3 (da) | Neuroaktive steroider, sammensætninger og anvendelse deraf | |
| DK3663292T3 (da) | Diphenylmethan-derivat i krystallinsk form | |
| PL3319612T3 (pl) | Oksysterole i sposoby ich stosowania | |
| DK3329118T3 (da) | Forbedringer vedrørende vindmøllevinger | |
| DK3221332T3 (da) | Fremstilling af steroide fxr-modulatorer | |
| HUE054542T2 (hu) | Glükokortikoid receptor inhibitor | |
| EP3394078A4 (fr) | Inhibiteurs de récepteurs glucocorticoïdes | |
| HUE054337T2 (hu) | C-3 és C-17 módosított triterpenoidok HIV-1 inhibitorokként | |
| EP3394079A4 (fr) | Inhibiteurs de récepteurs glucocorticoïdes | |
| HRP20260035T1 (hr) | Akustična suhomontažna ploča | |
| DK3680243T3 (da) | Pentacyklisk forbindelse | |
| HUE042413T2 (hu) | Kompozíció helyi alkalmazásra a hallójáratban | |
| EP3126378A4 (fr) | Antagonistes de stéroïdes cardiotoniques et procédés associés | |
| DK3234275T3 (da) | Gipsplade med pcm-hukommelsesmateriale | |
| HUE053364T2 (hu) | Mikronizált formájú N-palmitoil-D-glükózamin | |
| ES1161411Y (es) | Panel solar |